Active Not Recruiting PHASE4 INTERVENTIONAL 2-arm
NCT07325435
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists (Beta)
Beta Cell Function in Type 2 Diabetes in Black Patients: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Sponsor: MaryAnn Banerji
Conditions
Type 2 Diabetes (T2DM)
Interventions
GLP1-RA SGLT-2 inhibitor
Updated 1 time since 2026 Last updated: Jan 6, 2026 Started: Dec 21, 2024 Primary completion: Dec 31, 2027 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07325435, this PHASE4 trial focuses on Type 2 Diabetes (T2DM) and remains ongoing. Sponsored by MaryAnn Banerji, it has been updated 1 time since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Active Not Recruiting — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- MaryAnn Banerji
- The New York Community Trust
Data source: State University of New York - Downstate Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .